Tango治疗学获得“Buy”评分,目标为13.14美元,因为它发展了癌症治疗。 Tango Therapeutics receives "Buy" rating with a $13.14 target, as it develops cancer treatments.

坦戈治疗学(NASDAQ:TNGX)得到若干投资分析家的正面评价,维持“Buy”共识,目标价格为13.14美元。 Tango Therapeutics (NASDAQ:TNGX) received positive ratings from several investment analysts, maintaining a "Buy" consensus with a target price of $13.14. 该公司侧重于发展癌症治疗,在临床开发方面实施其牵头方案TNG908。 The company focuses on developing cancer treatments, with its lead program, TNG908, in clinical development. 机构投资者持有公司股票的78.99%,内部投资者在过去90天出售了价值1 913万美元的股票。 Institutional investors hold 78.99% of the company's stock, and insiders have sold $19.13 million worth of shares over the past 90 days.